- Home
- CNXC vs ACAD Comparison
CNXC vs ACAD Comparison
Compare CNXC & ACAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CNXC
- ACAD
- Stock Information
- Founded
- CNXC 1991
- ACAD 1993
- Country
- CNXC United States
- ACAD United States
- Employees
- CNXC N/A
- ACAD N/A
- Industry
- CNXC Computer Software: Prepackaged Software
- ACAD Biotechnology: Pharmaceutical Preparations
- Sector
- CNXC Technology
- ACAD Health Care
- Exchange
- CNXC Nasdaq
- ACAD Nasdaq
- Market Cap
- CNXC 3.6B
- ACAD 3.9B
- IPO Year
- CNXC N/A
- ACAD 2004
- Fundamental
- Price
- CNXC $35.97
- ACAD $24.40
- Analyst Decision
- CNXC Strong Buy
- ACAD Buy
- Analyst Count
- CNXC 5
- ACAD 21
- Target Price
- CNXC $69.00
- ACAD $29.00
- AVG Volume (30 Days)
- CNXC 1.2M
- ACAD 1.6M
- Earning Date
- CNXC 01-14-2026
- ACAD 11-05-2025
- Dividend Yield
- CNXC 4.00%
- ACAD N/A
- EPS Growth
- CNXC 54.10
- ACAD 98.53
- EPS
- CNXC 4.74
- ACAD 1.54
- Revenue
- CNXC $9,720,870,000.00
- ACAD $1,047,118,000.00
- Revenue This Year
- CNXC $4.00
- ACAD $14.12
- Revenue Next Year
- CNXC $3.24
- ACAD $11.80
- P/E Ratio
- CNXC $7.58
- ACAD $15.84
- Revenue Growth
- CNXC 3.40
- ACAD 12.69
- 52 Week Low
- CNXC $31.63
- ACAD $13.40
- 52 Week High
- CNXC $66.00
- ACAD $26.65
- Technical
- Relative Strength Index (RSI)
- CNXC 39.93
- ACAD 61.91
- Support Level
- CNXC $31.63
- ACAD $22.81
- Resistance Level
- CNXC $36.52
- ACAD $23.98
- Average True Range (ATR)
- CNXC 1.64
- ACAD 1.11
- MACD
- CNXC 0.45
- ACAD 0.09
- Stochastic Oscillator
- CNXC 58.93
- ACAD 94.28
About CNXC Concentrix Corporation
Concentrix Corp is a technology enabled company specialized in customer engagement and customer management. The company provides end-to-end capabilities, including CX process optimization, technology innovation and design engineering, front- and back-office automation, analytics and business transformation services to clients in five industry verticals. The Company's verticals are technology and consumer electronics, retail, travel and e-commerce, communications and media, banking, financial services and insurance, and healthcare. Geographically, the company operates in Philippines, Unites States, India, Frances and Others. Maximum revenue is from Technology and consumer electronics industry and geographically from Philippines.
About ACAD ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.